MG
VRTX icon

Mather Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Mather Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.98M Buy
4,438
+13
+0.3% +$6.06K 0.02% 227
2025
Q4 		$2.01M Buy
4,425
+86
+2% +$37.1K 0.02% 203
2025
Q3 		$1.7M Buy
4,339
+23
+0.5% +$9.61K 0.02% 218
2025
Q2 		$1.92M Buy
4,316
+170
+4% +$78.3K 0.02% 196
2025
Q1 		$2.01M Buy
4,146
+259
+7% +$121K 0.02% 182
2024
Q4 		$1.57M Sell
3,887
-128
-3% -$59.3K 0.02% 186
2024
Q3 		$1.87M Buy
4,015
+80
+2% +$38.4K 0.02% 170
2024
Q2 		$1.64M Buy
3,935
+398
+11% +$173K 0.02% 209
2024
Q1 		$1.44M Sell
3,537
-104
-3% -$44K 0.02% 179
2023
Q4 		$1.48M Buy
3,641
+49
+1% +$18.1K 0.02% 181
2023
Q3 		$1.25M Buy
3,592
+422
+13% +$148K 0.02% 187
2023
Q2 		$1.12M Buy
3,170
+287
+10% +$96.7K 0.02% 214
2023
Q1 		$908K Hold
2,883
– – 0.02% 223
2022
Q4 		$833K Buy
2,883
+102
+4% +$31.1K 0.02% 235
2022
Q3 		$805K Buy
2,781
+231
+9% +$66.5K 0.02% 226
2022
Q2 		$719K Buy
2,550
+264
+12% +$70.7K 0.02% 211
2022
Q1 		$596K Buy
+2,286
New +$543K 0.01% 233

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Mather Group's VRTX Position: Q1 2026 in Review

Mather Group increased its Vertex Pharmaceuticals (VRTX) stake by 0.29% in Q1 2026, buying an estimated $6.06K and bringing the position to 4,438 shares worth $1.98M. The position accounts for 0.02% of the portfolio, ranked #227.

Mather Group first reported a position in VRTX in Q1 2022 and has held it in 17 quarters since. The position peaked at $2.01M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Mather Group held 4,438 shares of Vertex Pharmaceuticals worth $1.98M as of Q1 2026.
  • Mather Group bought 13 Vertex Pharmaceuticals shares in Q1 2026, an estimated $6.06K.
  • Vertex Pharmaceuticals made up 0.02% of Mather Group's portfolio in Q1 2026, its #227 holding.
  • Mather Group first reported a position in Vertex Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • Mather Group's Vertex Pharmaceuticals position peaked at $2.01M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Mather Group's 13F filing for Q1 2026, filed 13 Apr 2026.